Author

A. Zinkina-Orikhan

Observed names: A. V. Zinkina-Orikhan, А. В. Зинкина-Орихан

Institution: BIOCAD (Russia)

Observed institution: BIOCAD (Russia)

ORCID: 0000-0002-8499-2232

Observed ORCID: 0000-0002-8499-2232

OpenAlex ID: A5002306102

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

2025 · K. Laktionov, A. Smolin, et al. · European Journal of Cancer · 12

Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA)

2026 · T. V. Shelekhova, J. Kumar, et al. · Clinical oncohematology · 1

OA11.05 Results of a Phase III Trial of Prolgolimab with Chemotherapy as First-Line Therapy for Patients with Advanced Non-Squamous NSCLC: DOMAJOR

2024 · K. Laktionov, A. Smolin, et al. · Journal of Thoracic Oncology

Pos0649 Efficacy and Safety of Levilimab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis: 1-year Results of Phase Iii, Double-blind, Placebo-controlled, Randomized Trial

2022 · V. Mazurov, M. Korolev, et al. · Annals of the Rheumatic Diseases

Фиксированная доза пролголимаба 250 мг один раз в три недели для пациентов с метастатической меланомой. Результаты клинического исследования фазы III FLAT

· Л. В. Демидов, Г. Ю. Харкевич, et al. · CyberLeninK (CyberLeninka)

Works count: 5

Citation count: 13

H-index: 1

I10-index: 1